氨基他达那非 | 385769-84-6

• 物质功能分类: 原料药 - 激素及调节内分泌功能类药 - 治疗男性勃起功能障碍药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 氨基他达那非
• 中文别名: 氨基苯丙吡咯
• 英文名称: (6R,12aR)-2-amino-6-(benzo[d][1,3]dioxol-5-yl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
• 英文别名: (6R,12aR)-2-amino-6-benzo[1,3]dioxol-5-yl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione；amino tadalafil；aminotadalafil；(6R,12aR)-2-amino-6-benzo[1,3]dioxo-5-yl-2,3,6,7,12,12a-hexahydropyrazino[1', 2':1,6]-pyrido[3,4-b]indole-1,4-dione；(2R,8R)-6-amino-2-(1,3-benzodioxol-5-yl)-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione
• CAS: 385769-84-6
• 化学式: C₂₁H₁₈N₄O₄
• 分子量: 390.398
• InChiKey: VUKJGAVIWMPOOJ-FOIQADDNSA-N

物化性质

• 熔点：
  280-282°C
• 沸点：
  678.9±65.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微加热）、DMSO（轻微加热）、甲醇（轻微加热）

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  29
• 可旋转键数：
  1
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 安全说明：
  S24/25
• 海关编码：
  29339900

制备方法与用途

氨基他达那非是有机合成和医药研发中的中间体，适用于实验室研究，是一种原料药，可用于治疗男性勃起功能障碍。

Amino Tadalafil 是 Tadalafil 的类似物。Tadalafil 是一种有效的磷酸二酯酶 5 (PDE5) 抑制剂，广泛用于治疗勃起功能障碍、肺动脉高压以及下尿路功能障碍等多种疾病。

反应信息

• 作为反应物：
  描述：

  氨基他达那非 在 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  CN106905318

  摘要：

  公开号：
• 作为产物：
  描述：

  D-色氨酸甲酯 在 三乙胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 反应 24.0h， 生成 氨基他达那非
  参考文献：
  名称：

  Drug to Genome to Drug: Discovery of New Antiplasmodial Compounds

  摘要：

  The dominant strategy for discovery of new antimalarial drugs relies on cell-free assays on specific biochemical pathways of Plasmodium falciparum . However, it appears that screening directly on the parasite is a more rewarding approach. The "drug to genome to drug" approach consists of testing a small set of structural analogues of a drug acting on human proteins that have plasmodial orthologues. Both man and plasmodium possess cyclic nucleotide phosphodiesterases (PDEs) that are key players of cell homeostasis. We synthesized and tested 40 analogues of tadalafil, a human PDE5 inhibitor, on P. falciparum in culture and obtained potent inhibitors of parasite growth. We discuss the structure-activity relationships, which support the hypothesis that our compounds kill the parasite via inhibition of plasmodial PDE activity. We also prove that antiplasmodial derivatives inhibit the hydrolysis of cyclic nucleotides of the parasite, validating the cAMP/cGMP pathways as therapeutic targets against Plasmodium falciparum .

  DOI：

  10.1021/jm1014617

文献信息

• Chemical compounds
  申请人：——

  公开号：US20030225094A1

  公开（公告）日：2003-12-04

  Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents. 1

  通用结构式（I）的化合物及其盐和溶剂合物的用途，作为治疗剂。
• US9920057B2
  申请人：——

  公开号：US9920057B2

  公开（公告）日：2018-03-20
• Drug to Genome to Drug: Discovery of New Antiplasmodial Compounds
  作者：Terence B. Beghyn、Julie Charton、Florence Leroux、Guillaume Laconde、Arnaud Bourin、Paul Cos、Louis Maes、Benoit Deprez

  DOI：10.1021/jm1014617

  日期：2011.5.12

  The dominant strategy for discovery of new antimalarial drugs relies on cell-free assays on specific biochemical pathways of Plasmodium falciparum . However, it appears that screening directly on the parasite is a more rewarding approach. The "drug to genome to drug" approach consists of testing a small set of structural analogues of a drug acting on human proteins that have plasmodial orthologues. Both man and plasmodium possess cyclic nucleotide phosphodiesterases (PDEs) that are key players of cell homeostasis. We synthesized and tested 40 analogues of tadalafil, a human PDE5 inhibitor, on P. falciparum in culture and obtained potent inhibitors of parasite growth. We discuss the structure-activity relationships, which support the hypothesis that our compounds kill the parasite via inhibition of plasmodial PDE activity. We also prove that antiplasmodial derivatives inhibit the hydrolysis of cyclic nucleotides of the parasite, validating the cAMP/cGMP pathways as therapeutic targets against Plasmodium falciparum .
• CN106905318
  申请人：——

  公开号：——

  公开（公告）日：——